Navigation Links
NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
Date:2/21/2013

LAWRENCE, Mass., Feb. 21, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced CE Mark approval for new high flow capabilities with the NxStage System One™.  With this approval, the Company expects to bring this advancement to customers in countries that recognize the CE Mark approval process later this year.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

The new high flow capabilities for the System One will enable dialysate flow rates which allow nephrologists expanded possibilities to adjust the duration and frequency of patient prescriptions with greater flexibility than they have today.

"Our new high flow capabilities advance the therapeutic flexibility of the System One as well as NxStage's leadership in home therapies," said Jeffrey Burbank , Chief Executive Officer, NxStage Medical, Inc. "By providing expanded therapy options, high flow enables NxStage therapy to be even better tailored to the clinical and lifestyle needs of a broader range of patients."

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) provide convenient use in patients' homes and give patients the freedom to travel with their therapy.  Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on the road. 

About NxStage Medical Inc.
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage products, visit, http://www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: NxStage Medical, Inc., ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
2. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
3. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
4. Robert Funari Joins NxStage Board of Directors
5. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
6. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
7. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
8. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
9. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
10. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
11. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, a ... medical devices, is pleased to announce that its Chief ... selected as a winner of the 2017 Executive Management ... and recognizes driven executives for their creative management ... The awards ceremony and celebration is on March 8, ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... and agreements entered into by the worlds leading healthcare companies. ... Description The Global ... access to partnering deals and agreements entered into by the world,s ... - Top deals by value - Deals listed by ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare Foundation ... to further positively impact the health and wellness of our community in San ... our duty to seriously consider releasing our assets beyond our 5% targeted distribution ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. ... distinguish between corrective action (CA) and preventive action (PA)? , The methods share ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
Breaking Medicine News(10 mins):